Treatment of adriamycin-induced nephropathy with erythropoietin and G-CSF

Journal of Nephrology

Volumn 26, Issue 3, 2013, Pages 534-539

  Modelli de Andrade, Luis Gustavo ^a   Marlene Viero, Rosa ^a   Cordeiro de Carvalho, Maria Fernanda ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Adriamycin; Erythropoietin; G CSF; Mobilization; Nephropathy; Stem cell

Indexed keywords

ALFAEPOETINA; ATAXIN 1; CD34 ANTIGEN; DOXORUBICIN; ENDOGLIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; KIDNEY FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RENAL PROTECTION; SCORING SYSTEM; STEM CELL MOBILIZATION;

ANIMALS; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY-STIMULATING FACTOR; KIDNEY DISEASES; MALE; MICE; MICE, INBRED BALB C;

EID: 84877987195     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000200     Document Type: Article

References (25)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17): 2038-2047.
2. Lin F, Cordes K, Li L, et al. Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol. 2003;14(5):1188-1199.
3. Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol. 2004;15(7):1794-1804.
4. Humphreys BD, Bonventre JV. Mesenchymal stem cells in acute kidney injury. Annu Rev Med. 2008;59(1):311-325.
5. Hopkins C, Li J, Rae F, Little MH. Stem cell options for kidney disease. J Pathol. 2009;217(2):265-281.
6. Nishida M, Hamaoka K. How does G-CSF act on the kidney during acute tubular injury? Nephron Exp Nephrol. 2006;104(4): e123-e128.
7. Fang TC, Alison MR, Cook HT, Jeffery R, Wright NA, Poulsom R. Proliferation of bone marrow-derived cells contributes to regeneration after folic acid-induced acute tubular injury. J Am Soc Nephrol. 2005;16(6):1723-1732.
8. Iwasaki M, Adachi Y, Minamino K, et al. Mobilization of bone marrow cells by G-CSF rescues mice from cisplatin-induced renal failure, and M-CSF enhances the effects of G-CSF. J Am Soc Nephrol. 2005;16(3):658-666.
9. Nishida M, Fujimoto S, Toiyama K, Sato H, Hamaoka K. Effect of hematopoietic cytokines on renal function in cisplatin-induced ARF in mice. Biochem Biophys Res Commun. 2004;324(1):341-347.
10. Stokman G, Leemans JC, Stroo I, et al. Enhanced mobilization of bone marrow cells does not ameliorate renal fibrosis. Nephrol Dial Transplant. 2008;23(2):483-491.
11. Zhang JJ, Yi ZW, Dang XQ, He XJ, Wu XC. [Mobilization effects of SCF along with G-CSF on bone marrow stem cells and endothelial progenitor cells in rats with unilateral ureteral obstruction]. Zhongguo Dang Dai Er Ke Za Zhi. 2007;9(2):144-148.
12. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev. 1992;72(2):449-489.
13. Bagnis C, Beaufils H, Jacquiaud C, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 2001;16(5):932-938.
14. Imamura R, Moriyama T, Isaka Y, et al. Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation. 2007;83(10):1371-1379.
15. Kapoor S. Beneficial effects of erythropoietin in ischemia-reperfusion injury. Acta Anaesthesiol Scand. 2008;52(8):1167-1168.
16. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003;17(12):1754-1755.
17. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation. 2004;110(8):1006-1012.
18. Kang DH, Park EY, Yu ES, Lee YS, Yoon KI. Renoprotective effect of erythropoietin (EPO): possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidney. Kidney Int. 2005;67(5):1683.
19. Noiri E, Nagano N, Negishi K, et al. Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats. Nephron Exp Nephrol. 2006;104(1):e6-e14.
20. Wang Y, Wang YP, Tay YC, Harris DC. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 2000;58(4):1797-1804.
21. Yalcin S, Müftüoǧ lu S, Cetin E, et al. Protection against cisplatin-induced nephrotoxicity by recombinant human erythropoietin. Med Oncol. 2003;20(2):169-174.
22. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102(4):1340-1346.
23. Bi B, Guo J, Marlier A, Lin SR, Cantley LG. Erythropoietin expands a stromal cell population that can mediate renoprotection. Am J Physiol Renal Physiol. 2008;295(4):F1017-F1022.
24. Dekel B, Zangi L, Shezen E, et al. Isolation and characterization of nontubular sca-1+lin-multipotent stem/progenitor cells from adult mouse kidney. J Am Soc Nephrol. 2006; 17(12):3300-3314.
25. Yasuda K, Park HC, Ratliff B, et al. Adriamycin nephropathy: a failure of endothelial progenitor cell-induced repair. Am J Pathol. 2010;176(4):1685-1695.